tiprankstipranks
Advertisement
Advertisement

ALMS Stock Latest News

Alumis price target raised to $40 from $38 at Chardan
The FlyAlumis price target raised to $40 from $38 at Chardan
14d ago
ALMS
Alumis Inc. (ALMS) Q1 Earnings Cheat Sheet
PremiumPre-Earnings
Alumis Inc. (ALMS) Q1 Earnings Cheat Sheet
15d ago
ALMS
Alumis price target raised to $39 from $38 at Morgan Stanley
PremiumThe Fly
Alumis price target raised to $39 from $38 at Morgan Stanley
18d ago
ALMS
Alumis price target raised to $51 from $49 at Wells Fargo
PremiumThe Fly
Alumis price target raised to $51 from $49 at Wells Fargo
18d ago
ALMS
Alumis price target raised to $34 from $32 at Guggenheim
PremiumThe Fly
Alumis price target raised to $34 from $32 at Guggenheim
18d ago
ALMS
Alumis downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe FlyAlumis downgraded to Neutral from Buy at H.C. Wainwright
18d ago
ALMS
Alumis reports Q1 net loss of $93.1M vs. net loss of $99.0M last year
Premium
The Fly
Alumis reports Q1 net loss of $93.1M vs. net loss of $99.0M last year
18d ago
ALMS
Compelling Efficacy and Safety of Alumis’s Oral TYK2 Candidate Envu Underpins Buy Rating and $25 Target
Premium
Ratings
Compelling Efficacy and Safety of Alumis’s Oral TYK2 Candidate Envu Underpins Buy Rating and $25 Target
2M ago
ALMS
Alumis falls -16.1%
PremiumThe Fly
Alumis falls -16.1%
2M ago
ALMS
Envu’s Compelling Efficacy and Superior Safety Profile Support Buy Rating on ALMS
PremiumRatings
Envu’s Compelling Efficacy and Superior Safety Profile Support Buy Rating on ALMS
2M ago
ALMS
Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James
PremiumThe Fly
Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James
2M ago
JNJ
TAK
Alumis price target raised to $55 from $50 at Oppenheimer
PremiumThe Fly
Alumis price target raised to $55 from $50 at Oppenheimer
2M ago
JNJ
TAK
Alumis Highlights Strong Phase 3 Psoriasis Results for Envudeucitinib
PremiumCompany AnnouncementsAlumis Highlights Strong Phase 3 Psoriasis Results for Envudeucitinib
2M ago
8K
ALMS
Alumis Inc. (ALMS): Buy Rating on Envu’s Strong Phase 3 Data and Attractive Risk‑Reward Ahead of 2026 FDA Submission
Premium
Ratings
Alumis Inc. (ALMS): Buy Rating on Envu’s Strong Phase 3 Data and Attractive Risk‑Reward Ahead of 2026 FDA Submission
2M ago
ALMS
Alumis price target lowered to $25 from $40 at H.C. Wainwright
Premium
The Fly
Alumis price target lowered to $25 from $40 at H.C. Wainwright
2M ago
ALMS
Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib
PremiumThe Fly
Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib
2M ago
ALMS
Alumis price target raised to $38 from $33 at Morgan Stanley
PremiumThe Fly
Alumis price target raised to $38 from $33 at Morgan Stanley
2M ago
ALMS
Alumis files automatic mixed securities shelf
PremiumThe Fly
Alumis files automatic mixed securities shelf
2M ago
ALMS
Alumis initiated with a Strong Buy at Raymond James
PremiumThe Fly
Alumis initiated with a Strong Buy at Raymond James
3M ago
ALMS
TYK2 Validation and Expanding Indications Drive Buy Rating and $40 Price Target for Alumis
PremiumRatingsTYK2 Validation and Expanding Indications Drive Buy Rating and $40 Price Target for Alumis
3M ago
ALMS
Alumis initiated with a Buy at Stifel
Premium
The Fly
Alumis initiated with a Buy at Stifel
3M ago
ALMS
Alumis rises 7.8%
Premium
The Fly
Alumis rises 7.8%
4M ago
ALMS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >